EAM Investors’s Standard BioTools LAB Stock Holding History

EAM Investors’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-473,982	Closed	-$1.37M	–	322
2023 Q3	$1.37M	Buy	+473,982	New	+$1.24M	0.27%	179
2019 Q3	–	Sell	-221,082	Closed	-$2.72M	–	268
2019 Q2	$2.72M	Sell	221,082 -165,772	-43%	-$2.11M	0.67%	34
2019 Q1	$5.14M	Buy	386,854 +149,767	+63%	+$1.58M	1.26%	1
2018 Q4	$2.04M	Buy	+237,087	New	+$1.85M	0.56%	46
2018 Q2	–	Sell	-78,554	Closed	-$459K	–	322
2018 Q1	$459K	Buy	+78,554	New	+$516K	0.08%	278
2015 Q2	–	Sell	-41,699	Closed	-$1.76M	–	353
2015 Q1	$1.76M	Buy	+41,699	New	+$1.65M	0.2%	211
2014 Q2	–	Sell	-33,654	Closed	-$1.48M	–	342
2014 Q1	$1.48M	Sell	33,654 -4,855	-13%	-$214K	0.27%	158
2013 Q4	$1.48M	Sell	38,509 -12,537	-25%	-$369K	0.26%	148
2013 Q3	$1.12M	Buy	+51,046	New	+$1M	0.22%	221

Other funds holding LAB

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EAM Investors's LAB Position: Q4 2023 in Review

EAM Investors sold out of Standard BioTools (LAB) in Q4 2023, closing a stake of 473,982 shares — an estimated $1.37M sold.

EAM Investors first reported a position in LAB in Q3 2013 and held it in 9 quarters. The position peaked at $5.14M in Q1 2019. 86 funds tracked by Wall St. Rank hold LAB as of Q4 2023.

EAM Investors reported no remaining Standard BioTools position as of Q4 2023 after selling out during the quarter.
EAM Investors sold 473,982 Standard BioTools shares in Q4 2023, an estimated $1.37M.
EAM Investors first reported a position in Standard BioTools in Q3 2013 and held it in 9 quarters.
EAM Investors's Standard BioTools position peaked at $5.14M in Q1 2019.
86 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2023.

Based on EAM Investors's 13F filing for Q4 2023, filed 14 Feb 2024.